66-year old male developed swollen lymph nodes about 10 days post 3rd dose of Pfizer; Cavanna et al. reported this case of Non-Hodgkin Lymphoma (NHL) Developing Shortly after mRNA COVID-19 Vaccination
by Paul Alexander
Was this case of NHL due to COVID mRNA gene vaccine? Also via the DNA platform? This is an example of the TURBO cancer we are referring to! This is the emergence of cancers now that defy explanation
‘We report on a 66-year-old man who presented with a right axillary lymphadenopathy approximately 10 days after receiving the third dose of the Pfizer BNT162b2 vaccine. The lymphadenopathy gradually enlarged, and physical examination and ultrasound (US) revealed one right axillary 6.99 cm and one right supraclavicular 2.36 cm lymphadenopathy.
Histologic examination of the right axillary nodule revealed anaplastic large-cell lymphoma that was ALK negative and CD30 positive. A total body computerized tomography (CT) scan, positron emission tomography (PET) and bone-marrow biopsy showed a stage-II non-Hodgkin lymphoma (NHL).
The patient was treated with chemotherapy and a scheme of Brentuximab Vedotin, Cyclophosphamide, Doxorubicin and Prednisone (BV-CHP) for six cycles and is now well and in complete remission.
The revision of the literature revealed eight additional cases of NHL developed shortly after COVID-vaccination.
There were four cases of diffuse large-B-cell lymphoma (DLBCL) (one in a patient who was a heart transplant recipient and developed an Epstein-Bar-virus-positive DLBCL), one case of extranodal NK/T-cell lymphoma, one patient with subcutaneous panniculitis-like T-cell lymphoma, one case of marginal zone B-cell lymphoma and one primary cutaneous anaplastic large-cell lymphoma (PC-ALCL). In five cases, the lymphoma developed after BNT162b2 mRNA vaccination, including one case after ChAdOx1 nCOV-19, one case after the adenovirus type 26 (Ad26) vaccine and one after mRNA-1273/Spikevax (ModernaTX).’
Swollen lymph nodes, or lymphadenopathy, is considered a common side effect of COVID-19 vaccination, more often observed following immunization with novel COVID-19 mRNA vaccines than other vaccines.